Product Description: BMS-748730 is an oral tyrosine kinase inhibitor. BMS-748730 inhibits tyrosine kinase activity by competing with the ATP binding site of the tyrosine kinase, which prevents the kinase from phosphorylating the substrate protein, thereby inhibiting signaling pathways associated with cell proliferation and tumor growth. BMS-748730 can be used in the study of certain types of cancer, including chronic myeloid leukemia (CML)[1].
Applications: Cancer-Kinase/protease
Formula: C22H26ClN7O3S
References: [1]Erp, P. H. van. Clinical pharmacology of the tyrosine kinase inhibitors imatinib and sunitinib. Leiden University Medical Center (LUMC), Leiden University. 2009, December 16.
CAS Number: 910297-57-3
Molecular Weight: 504.00
Research Area: Cancer
Target: c-Met/HGFR